These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Involvement of c-Jun N-terminal kinases activation in diabetic embryopathy.
    Author: Yang P, Zhao Z, Reece EA.
    Journal: Biochem Biophys Res Commun; 2007 Jun 08; 357(3):749-54. PubMed ID: 17449011.
    Abstract:
    The mechanisms for diabetic embryopathy are not well understood. JNK1/2 activation is increased in diabetic embryopathy, and antioxidants abolish JNK activation, and thus, ameliorate diabetic embryopathy. Phosphorylated SEK1 were significantly elevated in malformed embryos from diabetic mouse. In a dose-dependent manner, JNK inhibitor (SP600125) significantly reduced hyperglycemia-induced embryopathy. Malformation rates in embryos from the diabetic WT group were 15.6-fold higher than that in the non-diabetic WT control group. Jnk2 null mutant (JNKKO mice) was associated with a 71% reduction in the malformation rate of embryos under maternal diabetic conditions. Embryos cultured in 0.5mM sorbitol (JNK activator) had a malformation rate that was significantly higher than that of the control group. Pharmacological and genetic evidence from the present studies strongly support JNK activation being an indispensable mediator of diabetic embryopathy. JNK activation itself is sufficient to induce embryonic anomalies, and thus mimics the teratogenic effect of hyperglycemia.
    [Abstract] [Full Text] [Related] [New Search]